Last reviewed · How we verify

NCT05041816

Peripheral Nerve Responses to Focal Vibration and Implications in Pain and Mobility for Patients With Diabetic Peripheral Neuropathy

Withdrawn NA Last updated 6 March 2024
What this trial tests

NA trial testing Focal vibration therapy in Diabetic Peripheral Neuropathy. Withdrawn.

Timeline
1 September 2021
Primary endpoint
31 August 2022
31 August 2022

Quick facts

Lead sponsorUniversity of Oklahoma
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date1 September 2021
Primary completion31 August 2022
Estimated completion31 August 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Oklahoma

Who can join

Adults 45 to 80, any sex, with Diabetic Peripheral Neuropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to characterize the changes in peripheral nerve functions (sensory and motor) in patients with diabetic peripheral neuropathy, and examine the relations between the changes in nerve functions and changes in pain and mobility using focal vibration.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Focal vibration therapy

Trials testing the same drug.

Other recruiting trials for Diabetic Peripheral Neuropathy

Currently open trials in the same condition.

Other University of Oklahoma trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05041816.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing